Charles River Laboratories
CRLHeld by 2 superinvestors.
SEC 10-K · fundamentals
Business quality
as of 2025-12-27Valuation basis: trailing twelve months to 2026-06-27 — latest 10-K plus unaudited 10-Q filings.
- Revenue growth
- -0.9%
- Net margin
- -3.6%
- ROE
- -4.6%
- FCF margin
- 12.9%
Valuation · value band
Valuation
No usable market price is available, so this page does not place price on the value gauge.
Method & numbers
A conservative intrinsic-value band (zero-growth floor to growth-capped DCF) plus a tangible asset floor — not investment advice, not a buy/sell signal, and not a price target.
· reproduction $24.46
Moat Below asset base.
Graham earnings-power value (normalized NOPAT)$-23.44 – $-17.39 / sh
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
Years: TTM 2026-06-27, 2024, 2023, 2022, 2021
v1 simplifications: Maintenance capex (degraded) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Maintenance-capex methods diverge by 64% (> 50%); estimate is degraded. Share-based compensation is left as a real expense (not added back). Operating margin is below its multi-year average (cyclical/declining): normalized margin capped at the latest year — no peak-margin capitalization (audit #2).
Buffett owner-earnings value
Normalized owner earnings are non-positive over the years shown; earnings power cannot be capitalized.
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 9–11% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
Years: TTM 2026-06-27, 2024, 2023, 2022, 2021
v1 simplifications: Net income is below its multi-year average (cyclical/declining): normalized owner earnings anchored to the latest year — no peak-earnings capitalization (audit #2). Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). Maintenance-capex methods diverge by 64% (> 50%); estimate is degraded. One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the 9–11% band as a cost-of-equity proxy; no leverage premium applied. Net debt or owner earnings is unavailable, so no adjustment is made.
Asset floor: Reproduction value = tangible net assets + acquired-intangible reset proxy, ÷ diluted shares; tangible net assets alone are negative for this asset-light franchise (no R&D history to capitalize).
Moat reading: Franchise test compares earnings power (EPV) against reproduction value (tangible net assets + capitalized R&D). EPV well above reproduction value signals a moat; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
Growth value gated to zero — no moat or ROIIC ≤ WACC, so no growth value is credited.
Window TTM 2026-06-27, FY 2024, 2023, 2022, 2021 · discount band 9%–11% · normalized tax 15% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · diluted shares.
Valuation basis: trailing twelve months to 2026-06-27 — latest 10-K plus unaudited 10-Q filings.
How to read intrinsic valueSEC 13F · holders
Superinvestors Holding This Security
2 holders · $849.9M combined · this quarter +0 opened / -2 exited
- Value$508.3MWeight (prev→now)0.5% → 0.7% ▲
- Value$341.6MWeight (prev→now)2.8% → 3.4% ▲
SEC 13F · notes
Written summary
Written summary
Charles River Laboratories (CRL) is held by 2 of the superinvestors tracked on Compounder, with a combined $849.9M in reported 13F value. The largest position belongs to Bill Nygren, where it makes up 0.7% of the portfolio.
Other notable holders by value include John Rogers (3.4% of its book).
Over the latest quarter, 0 of the tracked filers opened a new position in CRL, 2 added to existing ones, 0 trimmed, and 2 sold out entirely.
Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-06-30. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.
SEC 13F · co-ownership
Also held by these investors
Investors holding Charles River Laboratories (CRL) also commonly hold →
- Capital One Financial CorpCOF2 holders
- Schwab (Charles) CorpSCHW2 holders
- Bank Of America CorpBAC2 holders
- Fiserv IncFISV2 holders
- Zimmer Biomet Holdings IncZBH2 holders
- Carlyle Group Inc/TheCG2 holders
See which stocks look cheap against a conservative value band. Browse all valued stocks
Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-14
Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.
Stay Updated
New-quarter 13F moves and valuation updates, to your inbox.